Key clinical point: Mutant huntingtin and plasma and cerebrospinal fluid levels of neurofilament light are useful biomarkers in Huntington’s disease.
Major finding: Levels of neurofilament light in plasma are correlated with those in cerebrospinal fluid.
Study details: A prospective, observational cohort study including 80 participants with and without Huntington’s disease.
Disclosures: No funding for this study was reported.
Rodrigues FB et al. AAN 2019, Abstract S16.003.